BioSpace News Archive

Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2022 financial results on Wednesday, February 22, 2023.

iSpecimen Inc. today announced that over the course of the second half of 2022, the Company added and onboarded seven new biospecimen providers to the iSpecimen Marketplace ® , for both banked and prospectively collected specimens.

CRISPR Therapeutics today announced that members of its senior management team are scheduled to participate in fireside chats at the following investor conferences in February.

T-knife Therapeutics, Inc. today announced it has appointed Behzad Kharabi Masouleh, M.D., as Chief Medical Officer.

RELIEF THERAPEUTICS Holding SA, provided an update on its financing strategy and the decision to voluntarily withdraw its Registration Statement on Form F-1 initially filed with the United States Securities and Exchange Commission on Aug. 23, 2022 in order to explore alternative options for financing, including non-dilutive sources of capital, with the goal of listing its ordinary shares on the Nasdaq Stock Market.

Immunovia announced that the consultation process regarding realigning its Swedish operations, announced on 19 January 2023, has been completed.

LEO Pharma Inc. today announced the Health Canada approval of Adtralza® (tralokinumab) for adolescent patients aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Swedish Orphan Biovitrum AB announced its report for the fourth quarter and full year of 2022

Arcutis Biotherapeutics, Inc. today announced that it will host a conference call and webcast at 4:30 p.m. ET on Tuesday, February 28, 2022 to report its fourth quarter and full year financial results, and provide a business update.

Fortress Biotech, Inc. today announced that it has entered into definitive agreements for the issuance and sale of 16.6 million shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules.